NextCure (NASDAQ:NXTC) Releases Quarterly Earnings Results, Misses Estimates By $0.39 EPS

NextCure (NASDAQ:NXTC) announced its quarterly earnings results on Tuesday. The company reported ($1.29) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.39), FiscalAI reports.

NextCure Trading Down 4.6%

NextCure stock traded down $0.29 during trading on Tuesday, hitting $5.98. The company had a trading volume of 81,525 shares, compared to its average volume of 673,282. NextCure has a 1-year low of $1.55 and a 1-year high of $15.74. The company’s 50 day simple moving average is $6.06 and its 200-day simple moving average is $7.67. The stock has a market cap of $21.59 million, a price-to-earnings ratio of -0.69 and a beta of 1.22.

Analysts Set New Price Targets

Several brokerages recently issued reports on NXTC. Weiss Ratings lowered shares of NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, October 26th. Wall Street Zen raised shares of NextCure from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of NextCure in a research note on Thursday, August 13th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $20.00.

Insider Transactions at NextCure

In other news, major shareholder Adar1 Capital Management, Llc purchased 5,626 shares of the firm’s stock in a transaction on Friday, October 23rd. The shares were bought at an average cost of $4.83 per share, for a total transaction of $27,173.58. Following the completion of the purchase, the insider directly owned 728,045 shares of the company’s stock, valued at approximately $3,516,457.35. This trade represents a 0.78% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders purchased a total of 15,537 shares of company stock valued at $77,603 over the last 90 days. 11.90% of the stock is owned by insiders.

About NextCure

NextCure, Inc. (NASDAQ: NXTC) is a clinical-stage biotechnology company focused on developing immunomedicines for the treatment of cancer. The company’s research is aimed at identifying and targeting biological mechanisms that suppress the immune system’s ability to recognize and attack tumor cells. NextCure’s product candidates have included NC318, an antibody designed to target Siglec-6, and NC410, a fusion protein intended to block the LAIR-1 immune-suppressive pathway. These programs have been evaluated in early-stage clinical studies involving patients with advanced solid tumors, with the goal of developing treatments that may restore or enhance anti-tumor immune responses.